Checklist: Head Case Lilly aims to expand the migraine-cure horizons.
Posted on Oct 4, 2017 10:00am

Promotion | Brought to you by Watch!

Pharmaceutical giant Eli Lilly and Company has an innovation in the pipeline that may provide relief to migraine sufferers either unsuitable for, or unresponsive to, standard prescription drug treatment. Currently in the final clinical trial phase and primed for submission for US regulatory approval in 2018 is Lasmiditan—unique because, unlike other migraine medications, its “mechanism of action” does not involve vasoconstriction (narrowing of the blood vessels).

While this first-of-a-kind treatment option could benefit many of the US’s more than 36 million migraine sufferers, it should be especially meaningful for cardiovascular patients, for whom vasoconstrictors are often contraindicated. For more on Lasmiditan, other meds-in-the-making and clinical developments, visit lilly.com.

Photo Credit: Dirima/Getty Images.